Alnylam Pharmaceuticals (NASDAQ:ALNY) : Zacks Investment Research ranks Alnylam Pharmaceuticals (NASDAQ:ALNY) as 4, which is a Sell recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.22, which indicates as a Strong Buy.
Alnylam Pharmaceuticals (NASDAQ:ALNY) : Average target price received by Alnylam Pharmaceuticals (NASDAQ:ALNY) is $114.5 with an expected standard deviation of $35.46. The most aggressive target on the stock is $180, whereas the most downbeat target is $80. 8 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Leerink Swann maintains its rating on Alnylam Pharmaceuticals (NASDAQ:ALNY).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Leerink Swann lowers the new price target from $120 per share to $107 per share. The rating by the firm was issued on May 3, 2016.
Alnylam Pharmaceuticals (NASDAQ:ALNY): stock turned positive on Tuesday. Though the stock opened at $53.42, the bulls momentum made the stock top out at $56.08 level for the day. The stock recorded a low of $53.08 and closed the trading day at $55.3, in the green by 5.33%. The total traded volume for the day was 957,964. The stock had closed at $52.5 in the previous days trading.
In an insider trading activity,The director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., Maraganore John sold 30,151 shares at $67.87 on April 19, 2016. The Insider selling transaction had a total value worth of $2,046,348. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.